Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Sayers Website

Thomas J. Sayers, Ph.D.

Selected Publications

1)  Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, Thomas CJ, de Kluyver RL, Sayers TJ, Ferrer M.
A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells.
J Biomol Screen. 17: 1231-42, 2012.
[Journal]
2)  Henrich CJ, Thomas CL, Brooks AD, Booth NL, Lowery EM, Pompei RJ, McMahon JB, Sayers TJ.
Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.
Apoptosis. 17: 79-89, 2012.
[Journal]
3)  Whitson EL, Sun H, Thomas CL, Henrich CJ, Sayers TJ, McMahon JB, Griesinger C, McKee TC.
Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima.
J. Nat. Prod. 75: 394-9, 2012.
[Journal]
4)  Sayers TJ.
Targeting the extrinsic apoptosis signaling pathway for cancer therapy.
Cancer Immunol. Immunother. 60: 1173-80, 2011.
[Journal]
5)  Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ.
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Mol. Cancer Res. 8: 729-38, 2010.
[Journal]
6)  Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Mol. Cancer Ther. 9: 1842-51, 2010.
[Journal]
7)  de Kluyver RL, Sayers TJ.
Breast cancer bone metastases: Combination therapy targeting cancer cells and the tumor microenvironment.
Cancer Biol Ther. 9: 551-3, 2010.
[Journal]
8)  Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM.
New flow cytometric assays for monitoring cell-mediated cytotoxicity.
Expert Rev Vaccines. 9: 601-16, 2010.
[Journal]
9)  Lee S, Yagita H, Sayers TJ, Celis E.
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Cancer Immunol. Immunother. 59: 1073-81, 2010.
[Journal]
10)  Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan S, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP.
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.
Blood. 116: 4192-201, 2010.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 11/19/2013.